Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
about
Immunogenic targets for specific immunotherapy in multiple myelomaTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsUp-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer.Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapyImmunogenicity of MHC Class I Peptides Derived from Leishmania mexicana Gp63 in HLA-A2.1 Transgenic (HHDII) and BALB/C Mouse Models2-thio-6-azauridine inhibits Vpu mediated BST-2 degradation.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.Immunogenicity of HLA-DR1 Restricted Peptides Derived from Leishmania major gp63 Using FVB/N-DR1 Transgenic Mouse ModelPotent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.Adoptive T-cell therapy for B-cell malignancies.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.Novel approaches in polyepitope T-cell vaccine development against HIV-1.Immunotherapy for multiple myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.Immunotherapy Strategies Against Multiple Myeloma.The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaEstablishment and Characterization of Paired Primary and Peritoneal Seeding Human Colorectal Cancer Cell Lines: Identification of Genes That Mediate Metastatic Potential
P2860
Q26859007-08E23927-D6E5-49C3-91E2-2D0BF0EB9B51Q27026161-2DB0D4DD-8857-4801-8DA9-CD5F9F9E9C7EQ33425484-C9F310AA-5556-430E-B474-5AB2CAB5F3AAQ33631179-03F3CF6B-D7D6-4242-AAB2-229E502B9384Q34079831-5BCD679D-F529-4020-8D62-6BF2F5545128Q35198753-1B9A600E-FF51-4C37-B4DC-B13BBC87DA6BQ35852574-01540931-2ED9-4ECF-A8CE-0E244BCC0230Q36093456-9C0B0512-AB8D-4BF8-A23B-4CB414B1B452Q36169794-FE1925E5-DED4-44A3-B7EF-398544EB505BQ36509894-F59DFFE6-BCD5-4460-AAD9-2F4910B3A317Q36646086-FF95AEB8-2D30-4AFE-8CE2-88AEEC02D770Q36835070-670844C3-A82B-45B0-93C7-B44F4D12D700Q37012554-7AFCC699-238E-4843-9CA2-F7A632DEC636Q37046880-B55675BE-6C5F-47A8-923A-9F455798E363Q37132866-0B4A5C91-FD60-456E-83CD-B07B446BC772Q37194598-73CA1FEE-9614-47E0-ABFE-69077FDBE999Q37810116-BE940345-3BF3-4EC4-8D43-F1CAE37372C7Q38014834-337010EF-8472-4CC3-ABD3-865284B560E3Q38059517-6C44B1FF-AA89-4D18-8D1D-F85F2B11C275Q38168900-CFEB2B74-16A4-4325-943E-D130267F73B2Q38177879-3D270D92-CAF3-4CC5-B468-0214277E9C57Q38246639-3A430848-8E3B-4329-8C84-EEA472C3A896Q38671390-7ED600F4-944D-4619-8C1D-B03CA36CB91EQ40169401-DC7194A1-A37D-4316-AD92-1C7372CC16FAQ40983895-F86E65C6-0E41-43B5-B6ED-F83D333989E5Q47143616-5B8FAD31-AA82-48F7-B3FC-3E54BEC09D0BQ49995864-5A3B8153-A1CD-4EC1-A00E-E4C84C9E3543Q57137807-F4ABABDB-4041-4200-BCC8-DCE60797FD50Q58782067-9031D39C-E73B-43C7-B46F-47A9A57BAB89
P2860
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@ast
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@en
type
label
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@ast
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@en
prefLabel
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@ast
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@en
P2093
P2860
P1476
Identification of a new HLA-A2 ...... y target for multiple myeloma.
@en
P2093
Alaviana Lupu
Anthony D Ho
Bernard Klein
Christian Kleist
Friedrich Cremer
Marion Moos
Maud Condomines
Michael Hundemer
Olaf Christensen
Peter Terness
P2860
P304
P356
10.1016/J.EXPHEM.2006.01.008
P577
2006-04-01T00:00:00Z